Base de dados : MEDLINE
Pesquisa : D09.698.718.450.600 [Categoria DeCS]
Referências encontradas : 3337 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 334 ir para página                         

  1 / 3337 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29374171
[Au] Autor:Rapicavoli JN; Blanco-Ulate B; Muszynski A; Figueroa-Balderas R; Morales-Cruz A; Azadi P; Dobruchowska JM; Castro C; Cantu D; Roper MC
[Ad] Endereço:Department of Microbiology and Plant Pathology, University of California, Riverside, CA, 92521, USA.
[Ti] Título:Lipopolysaccharide O-antigen delays plant innate immune recognition of Xylella fastidiosa.
[So] Source:Nat Commun;9(1):390, 2018 01 26.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Lipopolysaccharides (LPS) are among the known pathogen-associated molecular patterns (PAMPs). LPSs are potent elicitors of PAMP-triggered immunity (PTI), and bacteria have evolved intricate mechanisms to dampen PTI. Here we demonstrate that Xylella fastidiosa (Xf), a hemibiotrophic plant pathogenic bacterium, possesses a long chain O-antigen that enables it to delay initial plant recognition, thereby allowing it to effectively skirt initial elicitation of innate immunity and establish itself in the host. Lack of the O-antigen modifies plant perception of Xf and enables elicitation of hallmarks of PTI, such as ROS production specifically in the plant xylem tissue compartment, a tissue not traditionally considered a spatial location of PTI. To explore translational applications of our findings, we demonstrate that pre-treatment of plants with Xf LPS primes grapevine defenses to confer tolerance to Xf challenge.
[Mh] Termos MeSH primário: Imunidade Inata/imunologia
Lipopolissacarídeos/imunologia
Antígenos O/imunologia
Doenças das Plantas/imunologia
Imunidade Vegetal/imunologia
Xylella/imunologia
[Mh] Termos MeSH secundário: Perfilação da Expressão Gênica
Regulação da Expressão Gênica de Plantas/imunologia
Interações Hospedeiro-Patógeno/imunologia
Imunidade Inata/genética
Lipopolissacarídeos/metabolismo
Antígenos O/metabolismo
Doenças das Plantas/genética
Doenças das Plantas/microbiologia
Imunidade Vegetal/genética
Vitis/genética
Vitis/imunologia
Vitis/microbiologia
Xylella/metabolismo
Xylella/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Lipopolysaccharides); 0 (O Antigens)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180128
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-018-02861-5


  2 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29293563
[Au] Autor:Baranova DE; Levinson KJ; Mantis NJ
[Ad] Endereço:Department of Biomedical Sciences, University at Albany, Albany, NY, United States of America.
[Ti] Título:Vibrio cholerae O1 secretes an extracellular matrix in response to antibody-mediated agglutination.
[So] Source:PLoS One;13(1):e0190026, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vibrio cholerae O1 is one of two serogroups responsible for epidemic cholera, a severe watery diarrhea that occurs after the bacterium colonizes the human small intestine and secretes a potent ADP-ribosylating toxin. Immunity to cholera is associated with intestinal anti-lipopolysaccharide (LPS) antibodies, which are known to inhibit V. cholerae motility and promote bacterial cell-cell crosslinking and aggregation. Here we report that V. cholerae O1 classical and El Tor biotypes produce an extracellular matrix (ECM) when forcibly immobilized and agglutinated by ZAC-3 IgG, an intestinally-derived monoclonal antibody (MAb) against the core/lipid A region of LPS. ECM secretion, as demonstrated by crystal violet staining and scanning electron microscopy, occurred within 30 minutes of antibody exposure and peaked by 3 hours. Non-motile mutants of V. cholerae did not secrete ECM following ZAC-3 IgG exposure, even though they were susceptible to agglutination. The ECM was enriched in O-specific polysaccharide (OSP) but not Vibrio polysaccharide (VPS). Finally, we demonstrate that ECM production by V. cholerae in response to ZAC-3 IgG was associated with bacterial resistant to a secondary complement-mediated attack. In summary, we propose that V. cholerae O1, upon encountering anti-LPS antibodies in the intestinal lumen, secretes an ECM (or O-antigen capsule) possibly as a strategy to shield itself from additional host immune factors and to exit an otherwise inhospitable host environment.
[Mh] Termos MeSH primário: Matriz Extracelular
Vibrio cholerae O1/metabolismo
[Mh] Termos MeSH secundário: Testes de Aglutinação
Ensaio de Imunoadsorção Enzimática
Seres Humanos
Imunoglobulina G/imunologia
Microscopia Eletrônica de Varredura
Antígenos O/imunologia
Vibrio cholerae O1/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Immunoglobulin G); 0 (O Antigens)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190026


  3 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460348
[Au] Autor:Sizova OV; Kondakova AN; Shashkov AS; Knirel YA; Shaikhutdinova RZ; Ivanov SA; Platonov ME; Hurst MRH; Dentovskaya SV
[Ad] Endereço:N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991, Moscow, Russian Federation.
[Ti] Título:Structure and gene cluster of a tyvelose-containing O-polysaccharide of an entomopathogenic bacterium Yersinia entomophaga MH96 related to Yersinia pseudotuberculosis.
[So] Source:Carbohydr Res;445:93-97, 2017 Jun 05.
[Is] ISSN:1873-426X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:An O-polysaccharide was isolated from the lipopolysaccharide of an entomopathogenic bacterium Yersinia entomophaga MH96 by mild acid hydrolysis and studied by 2D NMR spectroscopy. The following structure of the branched tetrasaccharide repeating unit of the polysaccharide was established: where Tyv indicates 3,6-dideoxy-d-arabino-hexose (tyvelose). The structure established is consistent with the gene content of the O-antigen gene cluster. The O-polysaccharide structure and gene cluster of Y. entomophaga are related to those of some Y. pseudotuberculosis serotypes.
[Mh] Termos MeSH primário: Hexoses/química
Família Multigênica
Antígenos O/química
Yersinia pseudotuberculosis/química
Yersinia pseudotuberculosis/genética
[Mh] Termos MeSH secundário: Sequência de Carboidratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hexoses); 0 (O Antigens); 5658-12-8 (tyvelose)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  4 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28981517
[Au] Autor:Castillo DS; Rey Serantes DA; Melli LJ; Ciocchini AE; Ugalde JE; Comerci DJ; Cassola A
[Ad] Endereço:Instituto de Investigaciones Biotecnológicas - Instituto Tecnológico de Chascomús (IIB-INTECH), Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín, Buenos Aires, Argentina.
[Ti] Título:A recombinant O-polysaccharide-protein conjugate approach to develop highly specific monoclonal antibodies to Shiga toxin-producing Escherichia coli O157 and O145 serogroups.
[So] Source:PLoS One;12(10):e0182452, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Shiga toxin-producing Escherichia coli (STEC) is the major etiologic agent of hemolytic-uremic syndrome (HUS). The high rate of HUS emphasizes the urgency for the implementation of primary prevention strategies to reduce its public health impact. Argentina shows the highest rate of HUS worldwide, being E. coli O157 the predominant STEC-associated HUS serogroup (>70%), followed by E. coli O145 (>9%). To specifically detect these serogroups we aimed at developing highly specific monoclonal antibodies (mAbs) against the O-polysaccharide (O-PS) section of the lipopolysaccharide (LPS) of the dominant STEC-associated HUS serogroups in Argentina. The development of hybridomas secreting mAbs against O157 or O145 was carried out through a combined immunization strategy, involving adjuvated-bacterial immunizations followed by immunizations with recombinant O-PS-protein conjugates. We selected hybridoma clones that specifically recognized the engineered O-PS-protein conjugates of O157 or O145 serogroups. Indirect ELISA of heat-killed bacteria showed specific binding to O157 or O145 serogroups, respectively, while no cross-reactivity with other epidemiological important STEC strains, Brucella abortus, Salmonella group N or Yersinia enterocolitica O9 was observed. Western blot analysis showed specific recognition of the sought O-PS section of the LPS by all mAbs. Finally, the ability of the developed mAbs to bind the surface of whole bacteria cells was confirmed by flow cytometry, confocal microscopy and agglutination assays, indicating that these mAbs present an exceptional degree of specificity and relative affinity in the detection and identification of E. coli O157 and O145 serogroups. These mAbs may be of significant value for clinical diagnosis and food quality control applications. Thus, engineered O-PS specific moieties contained in the recombinant glycoconjugates used for combined immunization and hybridoma selection are an invaluable resource for the development of highly specific mAbs.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/uso terapêutico
Síndrome Hemolítico-Urêmica/tratamento farmacológico
Síndrome Hemolítico-Urêmica/microbiologia
Escherichia coli Shiga Toxigênica/imunologia
[Mh] Termos MeSH secundário: Ensaio de Imunoadsorção Enzimática
Escherichia coli O157/imunologia
Hibridomas
Antígenos O/imunologia
Sorogrupo
Sorotipagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (O Antigens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171022
[Lr] Data última revisão:
171022
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171006
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182452


  5 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28910350
[Au] Autor:Price EP; Sarovich DS; Webb JR; Hall CM; Jaramillo SA; Sahl JW; Kaestli M; Mayo M; Harrington G; Baker AL; Sidak-Loftis LC; Settles EW; Lummis M; Schupp JM; Gillece JD; Tuanyok A; Warner J; Busch JD; Keim P; Currie BJ; Wagner DM
[Ad] Endereço:Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia.
[Ti] Título:Phylogeographic, genomic, and meropenem susceptibility analysis of Burkholderia ubonensis.
[So] Source:PLoS Negl Trop Dis;11(9):e0005928, 2017 Sep.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The bacterium Burkholderia ubonensis is commonly co-isolated from environmental specimens harbouring the melioidosis pathogen, Burkholderia pseudomallei. B. ubonensis has been reported in northern Australia and Thailand but not North America, suggesting similar geographic distribution to B. pseudomallei. Unlike most other Burkholderia cepacia complex (Bcc) species, B. ubonensis is considered non-pathogenic, although its virulence potential has not been tested. Antibiotic resistance in B. ubonensis, particularly towards drugs used to treat the most severe B. pseudomallei infections, has also been poorly characterised. This study examined the population biology of B. ubonensis, and includes the first reported isolates from the Caribbean. Phylogenomic analysis of 264 B. ubonensis genomes identified distinct clades that corresponded with geographic origin, similar to B. pseudomallei. A small proportion (4%) of strains lacked the 920kb chromosome III replicon, with discordance of presence/absence amongst genetically highly related strains, demonstrating that the third chromosome of B. ubonensis, like other Bcc species, probably encodes for a nonessential pC3 megaplasmid. Multilocus sequence typing using the B. pseudomallei scheme revealed that one-third of strains lack the "housekeeping" narK locus. In comparison, all strains could be genotyped using the Bcc scheme. Several strains possessed high-level meropenem resistance (≥32 µg/mL), a concern due to potential transmission of this phenotype to B. pseudomallei. In silico analysis uncovered a high degree of heterogeneity among the lipopolysaccharide O-antigen cluster loci, with at least 35 different variants identified. Finally, we show that Asian B. ubonensis isolate RF23-BP41 is avirulent in the BALB/c mouse model via a subcutaneous route of infection. Our results provide several new insights into the biology of this understudied species.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Burkholderia/classificação
Burkholderia/efeitos dos fármacos
Microbiologia Ambiental
Variação Genética
Filogeografia
Tienamicinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Austrália
Burkholderia/genética
Burkholderia/isolamento & purificação
Infecções por Burkholderia/microbiologia
Infecções por Burkholderia/patologia
Modelos Animais de Doenças
Genótipo
Camundongos Endogâmicos BALB C
Tipagem de Sequências Multilocus
Antígenos O/genética
Papua Nova Guiné
Porto Rico
Tailândia
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (O Antigens); 0 (Thienamycins); FV9J3JU8B1 (meropenem)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005928


  6 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28817637
[Au] Autor:Yu X; Torzewska A; Zhang X; Yin Z; Drzewiecka D; Cao H; Liu B; Knirel YA; Rozalski A; Wang L
[Ad] Endereço:Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, TEDA College, Nankai University, Tianjin, P. R. China.
[Ti] Título:Genetic diversity of the O antigens of Proteus species and the development of a suspension array for molecular serotyping.
[So] Source:PLoS One;12(8):e0183267, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Proteus species are well-known opportunistic pathogens frequently associated with skin wound and urinary tract infections in humans and animals. O antigen diversity is important for bacteria to adapt to different hosts and environments, and has been used to identify serotypes of Proteus isolates. At present, 80 Proteus O-serotypes have been reported. Although the O antigen structures of most Proteus serotypes have been identified, the genetic features of these O antigens have not been well characterized. The O antigen gene clusters of Proteus species are located between the cpxA and secB genes. In this study, we identified 55 O antigen gene clusters of different Proteus serotypes. All clusters contain both the wzx and wzy genes and exhibit a high degree of heterogeneity. Potential functions of O antigen-related genes were proposed based on their similarity to genes in available databases. The O antigen gene clusters and structures were compared, and a number of glycosyltransferases were assigned to glycosidic linkages. In addition, an O serotype-specific suspension array was developed for detecting 31 Proteus serotypes frequently isolated from clinical specimens. To our knowledge, this is the first comprehensive report to describe the genetic features of Proteus O antigens and to develop a molecular technique to identify different Proteus serotypes.
[Mh] Termos MeSH primário: Genes Bacterianos
Antígenos O/genética
Proteus/imunologia
[Mh] Termos MeSH secundário: Reação em Cadeia da Polimerase
Proteus/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (O Antigens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183267


  7 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28735760
[Au] Autor:Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
[Ad] Endereço:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada; Health Biotechnology Division, National Institute for Biotechnology, Faisalabad, Pakistan; Department of Microbiology and Biotechnology, Abasyn University, Peshawar, Pakistan. Electronic address: s.amaza
[Ti] Título:First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
[So] Source:J Immunol Methods;450:27-33, 2017 Nov.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Efficacious typhoid vaccines for young children will significantly reduce the disease burden in developing world. The Vi polysaccharide based conjugate vaccines (Vi-rEPA) against Salmonella Typhi Vi positive strains has shown high efficacy but may be ineffective against Vi negative S. Typhi. In this study, for the first time, we report the synthesis and evaluation of polysaccharide-protein conjugates of Vi negative S. Typhi as potential vaccine candidates. Four different conjugates were synthesized using recombinant exoprotein A of Pseudomonas aeruginosa (rEPA) and human serum albumin (HSA) as the carrier proteins, using either direct reductive amination or an intermediate linker molecule, adipic acid dihydrazide (ADH). Upon injection into mice, a significantly higher antibody titer was observed in mice administrated with conjugate-1 (OSP-HSA) (P=0.0001) and conjugate 2 (OSP-rEPA) (P≤0.0001) as compared to OSP alone. In contrast, the antibody titer elicited by conjugate 3 (OSP -HSA) and conjugate 4 (OSP -rEPA) were insignificant (P=0.1684 and P=0.3794, respectively). We conclude that reductive amination is the superior method to prepare the S. Typhi OSP glycoconjugate. Moreover, rEPA was a better carrier protein than HSA. Thus OSP-rEPA conjugate seems to be efficacious typhoid vaccines candidate, it may be evaluated further and recommended for the clinical trials.
[Mh] Termos MeSH primário: ADP Ribose Transferases/imunologia
Toxinas Bacterianas/imunologia
Exotoxinas/imunologia
Antígenos O/imunologia
Polissacarídeos Bacterianos/imunologia
Salmonella typhi/imunologia
Vacinas Tíficas-Paratíficas/imunologia
Fatores de Virulência/imunologia
[Mh] Termos MeSH secundário: ADP Ribose Transferases/administração & dosagem
ADP Ribose Transferases/química
Aminação
Animais
Anticorpos Antibacterianos/sangue
Toxinas Bacterianas/administração & dosagem
Toxinas Bacterianas/química
Western Blotting
Eletroforese em Gel de Poliacrilamida
Exotoxinas/administração & dosagem
Exotoxinas/química
Feminino
Imunização
Esquemas de Imunização
Injeções Intraperitoneais
Camundongos Endogâmicos BALB C
Antígenos O/administração & dosagem
Antígenos O/química
Oxirredução
Espectroscopia de Prótons por Ressonância Magnética
Proteínas Recombinantes/imunologia
Albumina Sérica/imunologia
Albumina Sérica Humana
Vacinas Tíficas-Paratíficas/administração & dosagem
Vacinas Tíficas-Paratíficas/química
Vacinas Conjugadas/imunologia
Fatores de Virulência/administração & dosagem
Fatores de Virulência/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ALB protein, human); 0 (Antibodies, Bacterial); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (O Antigens); 0 (Polysaccharides, Bacterial); 0 (Recombinant Proteins); 0 (Serum Albumin); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vaccines, Conjugate); 0 (Virulence Factors); 0 (capsular polysaccharide, Salmonella); EC 2.4.2.- (ADP Ribose Transferases); EC 2.4.2.31 (toxA protein, Pseudomonas aeruginosa); ZIF514RVZR (Serum Albumin, Human)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170725
[St] Status:MEDLINE


  8 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28675263
[Au] Autor:Pakkanen SH; Kantele JM; Rombo L; Kantele A
[Ad] Endereço:Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
[Ti] Título:Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
[So] Source:Scand J Immunol;86(4):207-215, 2017 Oct.
[Is] ISSN:1365-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Secondary immunization with polysaccharide vaccines may imply a risk of hyporesponsiveness. Despite the wide use of typhoid Vi capsular polysaccharide vaccine, its potential tendency to hyporesponsiveness has been inadequately addressed. While previous studies have explored serum antibody responses, we applied a more sensitive approach, a single-cell assay for circulating plasmablasts, to compare primary and secondary responses. Twelve subjects received primary and booster doses of the Vi vaccine (Typherix ) at 30- to 37-month intervals. Plasmablasts specific to the Vi or typhoidal O antigens or cross-reactive with paratyphoid and non-typhoidal Salmonella strains were identified as antibody-secreting cells (ASC) with ELISPOT. Before vaccinations, none had plasmablasts specific to the antigens tested. Twelve of 12 subjects showed a Vi-specific response after primary, but only eight of 12 after booster vaccination. All responded to typhoidal O-9,12 antigen after both immunizations. The geometric mean of plasmablasts specific to the Vi antigen was 59 (95% CI 24-119) and 1 (0-54) IgA + IgG + IgM-ASC/10 peripheral blood mononuclear cell (PBMC) after primary and booster immunizations, respectively, and 20 (9-49) and 56 (29-103) to the O-9,12 antigen. We detected 1 (0-28) and 17 (6-36) ASC/10 PBMC cross-reactive with Salmonella Paratyphi A; 3 (0-30) and 22 (8-48) with S. Paratyphi B; 3 (0-29) and 18 (7-47) with S. Paratyphi C; 19 (10-34) and 51 (26-94) with Salmonella Enteritidis; and 1 (0-35) and 23 (9-52) with Salmonella Typhimurium, respectively. One-third of the vaccinees, although responding to the O-9,12 antigen, failed to respond to the Vi antigen after booster immunization, suggesting hyporesponsiveness in part of the vaccinees. The findings warrant further investigation.
[Mh] Termos MeSH primário: Epitopos/imunologia
Leucócitos Mononucleares/imunologia
Plasmócitos/imunologia
Polissacarídeos Bacterianos/imunologia
Salmonella typhi/imunologia
Febre Tifoide/imunologia
Vacinas Tíficas-Paratíficas/imunologia
[Mh] Termos MeSH secundário: Adulto
Células Cultivadas
Reações Cruzadas
ELISPOT
Feminino
Seres Humanos
Imunização Secundária
Masculino
Meia-Idade
Antígenos O/imunologia
Análise de Célula Única
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Epitopes); 0 (O Antigens); 0 (Polysaccharides, Bacterial); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vi polysaccharide vaccine, typhoid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12583


  9 / 3337 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28647986
[Au] Autor:Yu F; Wang RN; Chen X; Zheng SF; Wang YY; Chen Y
[Ad] Endereço:Key Laboratory of Clinical in Vitro Diagnostic Techniques of Zhejiang Province, Department of Clinical Laboratory, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
[Ti] Título:[Studies on the serum types and identification efficiency on Diarrheagenic isolated from diarrhea patients, in Zhejiang province].
[So] Source:Zhonghua Liu Xing Bing Xue Za Zhi;38(6):800-804, 2017 Jun 10.
[Is] ISSN:0254-6450
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the serotypes of Diarrheagenic (DEC) isolated from diarrheal patients in Zhejiang province and to explore the identification efficiency of serological screening methods. Serological agglutination tests were carried out in 696 strains of DEC (through the identification of virulence genes) which were selected from the Infectious Diarrhea Pathogen Monitoring Network Strain Bank of Zhejiang province, from July 2009 to June 2013. Results of virulence genes, serological identification and classification were compared. Among the 696 isolates of DEC, O antigen type was identified in 288 (41.4 ) isolates which belonging to 35 different 'O' serum types. H antigen was seen in 171 (24.6 ) isolates and determined as having 21 types. The agglutination rates of EAEC, ETEC, EPEC and EHEC isolates were 31.9 (130/408), 70.6 (127/180), 31.5 (29/92) and 14.3 (2/14), respectively and belonged to 30, 18, 15 kinds of 'O' sero-groups, respectively. One EHEC isolate was identified as O157∶H7. Serum groups were diverse for EAEC and EPEC, while relatively concentrated on ETEC. Different types of DEC might belong to the same sero-group or type. Among the 74 strains of DEC available for classification serologically, 41 isolates were in consistent with virulence gene identification and another 33 strains were not. The sero-group/type of DEC strains in Zhejiang were varied. Based on the serological screening method alone, DEC classification might end in getting the wrong answer, thus we would recommend the use of virulence gene for the purpose of identification.
[Mh] Termos MeSH primário: Diarreia/microbiologia
Infecções por Escherichia coli/diagnóstico
Escherichia coli/classificação
Escherichia coli/genética
Reação em Cadeia da Polimerase Multiplex/métodos
Antígenos O/análise
[Mh] Termos MeSH secundário: Testes de Aglutinação
Disenteria/microbiologia
Escherichia coli/isolamento & purificação
Infecções por Escherichia coli/microbiologia
Genes Bacterianos
Seres Humanos
Sensibilidade e Especificidade
Sorotipagem
Virulência
Fatores de Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (O Antigens); 0 (Virulence Factors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0254-6450.2017.06.022


  10 / 3337 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28535267
[Au] Autor:Charles RC; Nakajima R; Liang L; Jasinskas A; Berger A; Leung DT; Kelly M; Xu P; Kovác P; Giffen SR; Harbison JD; Chowdhury F; Khan AI; Calderwood SB; Bhuiyan TR; Harris JB; Felgner PL; Qadri F; Ryan ET
[Ad] Endereço:Division of Infectious Diseases, Massachusetts General Hospital.
[Ti] Título:Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh.
[So] Source:J Infect Dis;216(1):125-134, 2017 Jul 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Cholera is a severe dehydrating illness of humans caused by toxigenic strains of Vibrio cholerae O1 or O139. Identification of immunogenic V. cholerae antigens could lead to a better understanding of protective immunity in human cholera. Methods: We probed microarrays containing 3652 V. cholerae antigens with plasma and antibody-in-lymphocyte supernatant (ALS, a surrogate marker of mucosal immune responses) from patients with severe cholera caused by V. cholerae O1 in Bangladesh and age-, sex-, and ABO-matched Bangladeshi controls. We validated a subset of identified antigens using enzyme-linked immunosorbent assay. Results: Overall, we identified 608 immunoreactive V. cholerae antigens in our screening, 59 of which had higher immunoreactivity in convalescent compared with acute-stage or healthy control samples (34 in plasma, 39 in mucosal ALS; 13 in both sample sets). Identified antigens included cholera toxin B and A subunits, V. cholerae O-specific polysaccharide and lipopolysaccharide, toxin coregulated pilus A, sialidase, hemolysin A, flagellins (FlaB, FlaC, and FlaD), phosphoenolpyruvate-protein phosphotransferase, and diaminobutyrate-2-oxoglutarate aminotransferase. Conclusions: This study is the first antibody profiling of the mucosal and systemic antibody responses to the nearly complete V. cholerae O1 protein immunome; it has identified antigens that may aid in the development of an improved cholera vaccine.
[Mh] Termos MeSH primário: Cólera/imunologia
Imunidade nas Mucosas
Imunoglobulina A/sangue
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Vibrio cholerae O1/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Antibacterianos/sangue
Formação de Anticorpos
Bangladesh/epidemiologia
Estudos de Casos e Controles
Cólera/epidemiologia
Toxina da Cólera/sangue
Feminino
Flagelina/sangue
Seres Humanos
Leucócitos Mononucleares/metabolismo
Masculino
Meia-Idade
Membrana Mucosa/imunologia
Antígenos O/sangue
Sistema Fosfotransferase de Açúcar do Fosfoenolpiruvato/sangue
Fosfotransferases (Aceptor do Grupo Nitrogenado)/sangue
Reprodutibilidade dos Testes
Vibrio cholerae O1/isolamento & purificação
Vibrio cholerae O139/isolamento & purificação
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Immunoglobulin M); 0 (O Antigens); 12777-81-0 (Flagellin); 9012-63-9 (Cholera Toxin); EC 2.7.1.- (Phosphoenolpyruvate Sugar Phosphotransferase System); EC 2.7.3.- (Phosphotransferases (Nitrogenous Group Acceptor)); EC 2.7.3.9 (phosphoenolpyruvate-protein phosphotransferase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171117
[Lr] Data última revisão:
171117
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix253



página 1 de 334 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde